Why the study?
Does the combination of SKF 107260 and ASA improve inhibition of platelet aggregation and secretion in human whole blood compared to either agent alone?
Does the combination of SKF 107260 and ASA improve inhibition of platelet aggregation and secretion in human whole blood compared to either agent alone?
The combination of the GP IIb/IIIa receptor antagonist SKF 107260 and ASA provides augmented anti-aggregatory effects in human whole blood.
Answers are grounded in this paper and cite their sources.
May enhance platelet inhibition in vitro; leaves open whether combination improves clinical outcomes.
SKF 107260 is a potent pentapeptide antagonist of the platelet membrane glycoprotein receptor GP IIb/IIIa. The in vitro platelet inhibitory effects of SKF 107260, acetylsalicylic acid (ASA), and their combination, on collagen-induced platelet aggregation and secretion (ATP release) were assessed in human whole blood. Additionally, the concentration-response relationships for these inhibitors were compared for males and females in order to explore gender differences in platelet responsiveness. SKF 107260 caused a concentration-dependent inhibition of platelet aggregation which was significant at concentrations > or = 30 nM. ASA also caused a concentration-dependent inhibition of platelet aggregation which was significant at concentrations > or = 1 mg/dl. The addition of ASA 1 mg/dl to increasing concentrations of SKF 107260 resulted in a more pronounced inhibition of platelet aggregation than when either agent was used alone. These data suggest a pharmacologic interaction, especially at SKF 107260 concentrations < or = 30 nM. Since ATP release was significantly inhibited at concentrations > or = 1 nM, platelet secretion appears to be more sensitive than aggregation to inhibition by SKF 107260. These data suggest that platelet secretion in response to collagen is dependent on the aggregation response mediated by GP IIb/IIIa. In conclusion, SKF 107260 is a potent inhibitor of both whole blood platelet aggregation and secretion and these anti-aggregatory effects may be augmented by concomitant ASA administration.
No takes yet. Share an insight, caveat, or question.
Freed et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: